Podcasts about Ascent

Welcome to Part 4 of our 5-part mini-series, "The Ascent."It is easy to find peace when the ground is flat and the sun is shining, but life isn't always a meadow—sometimes it is a mountain. In today's session, we leave the comfort of the Open Field to face the incline, not to conquer the mountain, but to discover the strength that has been hiding in your heart all along.This guided meditation is designed to help you build resilience and navigate the "boulders" in your path—whether they are worries, fears, or difficult people. We will practice "Altitude Breathing" to oxygenate your courage and visualize a climb that shifts your perspective from the problem to the progress you have made.In this episode, we will cover:Altitude Breathing: A breathwork technique to calm panic when the path gets steep.The Boulder Visualization: Learning to navigate around obstacles rather than fighting them.The Plateau: Recognizing how far you have come.Peak Affirmations: Use these affirmations when you feel the weight of the climb:"I am stronger than the obstacles in my way." "I take life one step at a time." "I trust my ability to figure things out." "I do not fear the climb; I embrace the growth." "I am rising." Martin's 3 Caring Tips for a Happier Life: Inspired by the climber's mindset, here is how to bring this resilience into your daily routine:Lighten Your Pack: A climber never carries what they don't need. Identify one "mental weight" you are carrying—a grudge, a worry about next week, or guilt from yesterday. Visualize taking it out of your backpack and leaving it on the side of the trail.The "Look Back" Rule: We are often so focused on the summit that we forget to appreciate the altitude we've already gained. If you feel stuck, stop and write down three things you have achieved in the last year.Choose Your Route: If you hit a roadblock, don't bang your head against it. Be like water and go around. Ask yourself, "What is the other way to solve this?" There is always another path up the mountain.Ready to go deeper? Access The Anxiety Circuit Breaker early here:https://calminganxietypodcast.systeme.io/letter(Use code RELAX for a launch discount)Coming Up Next: In the final episode (Part 5), we will reach The Summit to see the world from a brand new perspective.Connect with the Show: If this climb helped you find your strength, please subscribe so you don't miss the finale. Smile often, think positive thoughts, and in everything... be kind.

We review the recent ASCENT-04/Keynote-D19 publication of sacituzuab govitecan + pembrolizumab for PD-L1 CPS of 10% and above TNBC compared to chemo + pembrolizumab alone. Also, a quick recap of ASCO GI earlier this month with mentions of zanidatamab and zolbetuximab. Finally, a check-in on The Pitt.

Are Trump's pharmaceutical policies a seismic revolution, or just hot air? Will he succeed in lowering drug prices in 2026? Will manufacturing shift to the US? And how will all of this impact Europe and China? ING's Diederik Stadig and Stephen Farrelly answer these questions and more in this week's THINK aloud.

Have a Social with the Saints! Receive encouragement for your daily life as we meet & discuss St. Marianne Cope,  a role model of faith who famously cared for those with Leprosy on the Hawaiian islands. How will she help and inspire you? Be encouraged and inspired in your daily life! Get a free quote card and pamphlet of St. Marianne Cope here. We invite you to share them with friends and family. To learn more about St. Marianne Cope, click here for the official website for the Saint Marianne Cope Shrine & Museum. We want to hear from you! What struck you about St. Marianne Cope? Please send us your feedback to join the conversation by email at ministry@pilgrimcenterofhope.org The official Socials with the Saints theme song is "Hero's Ascent" by Chris Haugen. Used with permission. Thanks for listening, and remember, you are never alone in the communion of the saints! May God bless you. Help us spread hope!

Greg makes real progress about ascent, and he ascends to progress. Episode 1316 Greg's new book: Inspired Imperfection Dan's new book: Confident Humility Send Questions To: Dan: @thatdankent Twitter: @reKnewOrg Facebook: ReKnew Email: askgregboyd@gmail.com Links: Greg's book:"Crucifixion of the Warrior God" Website: ReKnew.org  

In this conversation, the hosts discuss the innovative game Ascent Rivals, a fusion of racing, combat, and strategy, developed with a focus on traditional gaming experiences. The developers share their backgrounds in game development and esports, emphasising community engagement and organic growth during the alpha phase. They explore funding strategies, integrating Web3 elements, and the technical aspects of building on the Cardano blockchain, aiming to create a game that appeals to both traditional and Web3 gamers.TakeawaysAscent Rivals is a fusion game combining racing, combat, and strategy.The development team has a strong background in traditional gaming and esports.Community engagement is crucial for game development in the Web3 space.The game aims to attract traditional gamers rather than just Web3 enthusiasts.Funding comes from grants, consulting work, and self-funding.The team is focused on organic growth and community feedback during alpha testing.Web3 elements will be integrated seamlessly to enhance the player experience.The game is designed to be fun and engaging without relying on crypto incentives.Technical advancements are leveraged to achieve ambitious goals with a small team.The vision includes making Ascent Rivals a recognised esports title.Learn more about the game and join the community:https://www.ascentrivals.com/Chapters00:00Introduction to Ascent Rivals02:47Game Development Background and Vision05:58Community Engagement and Feedback08:49Funding and Development Strategy12:05Web3 Integration and Onboarding14:56Technical Aspects and Future PlansDISCLAIMER: This content is for informational and educational purposes only and is not financial, investment, or legal advice. I am not affiliated with, nor compensated by, the project discussed—no tokens, payments, or incentives received. I do not hold a stake in the project, including private or future allocations. All views are my own, based on public information. Always do your own research and consult a licensed advisor before investing. Crypto investments carry high risk, and past performance is no guarantee of future results. I am not responsible for any decisions you make based on this content.

UConn breezed through its toughest stretch in the new year, dispatching second-place Villanova with ease and then notching its largest margin of victory ever against Notre Dame. We talk about KK Arnold's continued ascent after playing the best game of her career on Monday, Sarah Strong hitting 1,000 career points and Ashlynn Shade quietly putting together another good performance. We also discuss the Huskies' 2015 and 2016 national championship teams, get into the latest updates on Morgan Cheli and Ice Brady, then take a deep dive into bracketology and future schedules. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit chasingperfection.substack.com

This week, Pastor Abraham leads us through Psalm 121, continuing our series focusing on the Psalms of Ascent.

This week, we launch into a new series, looking at the Psalms of Ascent. Pastor Abraham leads us off with Psalm 120, speaking on the song written about The God of Peace.

If you have to pick, which elite status would you prefer, American or Alaska? How does this new edit credit work? We answered these and many other questions on the Ask Us Anything hosted live on January 7th of 2026.(03:34) - ​​Curious to hear what 'coupons/credits' you just let go of, without redeeming by 12/31. I didn't use my first The Edit credit and can't stop feeling guilty.(05:48) - How does this new edit credit work, because there are so many different answers...?You can see a map of The Edit by Chase Travel℠ properties here:(10:05) - ​​What do you think about the Apple Card takeover by Chase?See Greg's old post about the Apple Card here(12:48) - Have any of you proactively lowered the credit limit on a card?(17:17) - ​Do you think that the Bilt leak is real or fake? There are 3 different leaks right nowFind coffee break episode 86 about Bilt leaks here(18:44) - ​​I started with Chase (I'm newer to points), but I'm curious what you all think are the best uses of each of the ecosystems and/or what you personally use them for?Learn more about Citi transfer partners here(23:05) - ​​Last October, I booked a stay at the Hyatt Regency Rome for mid-April 2026, not realizing it was a new hotel. The website now shows reservations starting May 1, 2026, with no availability in April. ​​I'm concerned about whether my reservation will be honored. If the hotel isn't ready, will Hyatt relocate me, and how soon would I be notified? I've booked a backup hotel, but would appreciate any tips(25:25) - Do the miles and points conventions mention things that aren't normally discussed in free podcasts like yours?(26:53) - ​​Alaska miles redemption for Europe often entails BA metal that has high fees. Any tips on European redemptions? Or are Alaska miles mainly for AA or Asian partner awards?(35:22) - ​​Does that PLAT airline credit still work for United Travel Bank this year?See our "Amex airline reimbursement fees...what still works?" post here(36:53) - ​​Venture X travel credit is a discount rather than a credit. If I have two bookings and have to cancel the one booked with the discount, can I retroactively have them lower the second booking?(37:25) - ​​What is everyone's US Bank strategy? I cashed mine out at 1.5x(42:00) - If you have to pick, which elite status would you prefer, American or Alaska?Find our podcast episode about American vs Alaska here(48:01) - Find coffee break episode 86 about Bilt leaks here(48:24) - Tim - In what cases is it worthwhile to keep both Atmos cards (Summit and Ascent)(54:10) - ​​For 2026, any new programs you're prioritizing for earning or status? E.g. Citi to PHR, Atmos, etc?Visit https://frequentmiler.com/subscribe/ to get updated on in-depth...

In the episode I discuss the Psalms of Ascent. Psalms 120-134.

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and vice chair of academic affairs here at the City of Hope Comprehensive Cancer Center, Los Angeles. Today, I'm thrilled to be joined by Dr. Hope Rugo, an internationally renowned breast medical oncologist and my colleague here at City of Hope, where she leads the Women's Cancers Program and serves as division chief of breast medical oncology. Dr. Rugo is going to share with us exciting advances in antibody-drug conjugates (ADCs) that are expanding treatment options in various breast cancer types. She'll also address some of the complex questions arising in the new era of oral SERDs (selective estrogen receptor degraders) that are revolutionizing treatment in the hormone receptor-positive breast cancer space. Our full disclosures are available in the transcript of this episode.  Dr. Rugo, welcome, and thanks so much for being on the podcast today. Dr. Hope Rugo: Thank you. Pleasure to be here. Dr. Monty Pal: So, I'm going to switch to first names if you don't mind.  The first topic is actually a really exciting one, Hope, and this is antibody-drug conjugates. I don't know if I've ever shared this with you, but I actually started my training at UCLA, I was a med student and resident there, and it was in Dennis Slamon's lab. I worked very closely with Mark Pegram and a handful of others. This is right around the time I think a lot of HER2-directed therapies were really evolving initially in the clinics. Now we've got antibody-drug conjugates. Our audience is well-familiar with the mechanism there but tell us about how ADCs have really started to reshape therapy for HER2-positive breast cancer. Dr. Hope Rugo: Yeah, I mean, this is a really great place to start. I mean, we have had such major advances in breast cancer just this year, I think really changing the paradigm of treating patients. But HER2-positive disease, we've been used to having sequenced success of new agents. And I think the two biggest areas where we've made advances in HER2-positive disease, which were remarkably advanced this year in 2025, have been in antibody-drug conjugates with trastuzumab deruxtecan and with new oral tyrosine kinase inhibitors (TKIs) that have less of a target on EGFR and more on HER2, so they have an overall more tolerable toxicity profile and therefore a potentially better efficacy in the clinic. At least that's what we're seeing with these new strategies that we couldn't really pursue in the past because of toxicities of the oral TKIs. So, although our topic is ADCs, I'm going to include the TKI because it's so important in our thinking about treating HER2-positive disease. In the metastatic setting, we've seen these remarkable improvements in progression-free and overall survival in the second-line setting with T-DXd, or trastuzumab deruxtecan, compared to T-DM1. And then sequencing ADCs with giving T-DXd after T-DM1 was better than an oral tyrosine kinase or a trastuzumab combination with standard chemotherapy. That was DESTINY-Breast03 and DESTINY-Breast02. So, then we've had other trials since then, and T-DXd has moved into the early-stage setting, which I'll talk about in just a moment. But the next big trial for T-DXd in HER2-positive disease was moving it to the first-line setting to supplant what has become an established treatment for now quite a long time: the so-called CLEOPATRA regimen, which used the combined antibodies trastuzumab, pertuzumab with a taxane as first-line therapy. And then we've proceeded on with maintenance with ongoing HP for patients with responding or stable disease. And we'd seen long-term data showing, you know, at 8 years there was a group of patients whose cancers had never progressed and continued improved overall survival. So, T-DXd was studied in DESTINY-Breast09, either alone or in combination with pertuzumab compared to THP. The patient population had received a little bit more prior treatment, but interestingly, not a lot compared to CLEOPATRA. And they designed the trial to be T-DXd continued until progression with or without pertuzumab versus THP, which would go for six cycles and then stop around six cycles, and then stop and continue HP. Patients who had hormone receptor-positive disease could use hormone therapy, and this is one of the issues with this dataset because, surprisingly in this dataset and one other I'll mention, very few patients took hormone therapy. And even in the maintenance trial, the HER2CLIMB-05, less than 50% took hormone therapy as maintenance. This is kind of shocking to me and highlights an area of really important education, that outcome is improved when you add endocrine therapy for hormone receptor-positive HER2-positive metastatic disease in the maintenance phase, and it's a really important part of treatment. But suffice it to say, you know, you're kind of studying continued chemo versus stopping chemo in maintenance. And T-DXd, as we all expected, in combination with pertuzumab was superior to THP in terms of progression-free survival, really remarkably improved. And you could stop the chemo with toxicity, but most people continued it with T-DXd. Again, not a lot of people got hormone therapy, which is an issue, and you stop the chemo in the control arm. So, this has brought up a lot of interest in trying to use T-DXd as an induction and then go to maintenance, much as we do with the CLEOPATRA regimen with hormone therapy. But it brings up another issue. So first, T-DXd is superior; it's a great treatment. Not everybody needs to have it because we don't know whether it's better to give T-DXd first or second with progression - that we need a little bit longer follow-up. But just earlier this week, interestingly, the third week of December, the U.S. FDA approved T-DXd in the DESTINY-Breast09 approach with pertuzumab. So as I mentioned earlier, there was a T-DXd-alone arm; that arm has not yet reported. So very interesting, we don't know if you need pertuzumab or not. So what about the maintenance? That's the other area where we've made a huge advance here. So, we all want to stop chemo and we want to stop T-DXd. You don't want somebody being nauseated for two years while they're on treatment, and also there's a small number of patients with mostly de novo metastatic HER2-positive disease who are cured of their disease. We'd like to expand that, and I think these new drugs give us the opportunity to improve the number of patients who might be cured from metastatic disease. So the first maintenance study we saw was adding palbociclib, the CDK4/6 inhibitor, to endocrine therapy and HP, essentially. There, we had a remarkable improvement in progression-free survival difference of 15.2 months: 29 to 44 months, really huge. At San Antonio this year, we saw data with this oral tyrosine kinase inhibitor tucatinib, already showed it was great in a triplet, but as maintenance in combination with HP, it showed also a remarkable improvement in progression-free survival. But the numbers were all shifted down. So in PATINA, the control arm was in the 24-month range; here it was the tucatinib-HP arm that was in the 25 months and 16 months for control. So there was a differential benefit in ER-negative and ER-positive disease. So I think we're all thinking that our ideal approach moving forward would be to give T-DXd to most patients, we see how they do, and treat to best response. And then, stop the T-DXd, start HP, trastuzumab, pertuzumab for ER-negative, with tucatinib for ER-positive with palbociclib. We also have early data that suggests that both approaches may reduce the development of brain metastases, an issue in HER2-positive disease, and delay time to progression of brain metastases as seen in HER2CLIMB-05 in very early data - small numbers, but still quite intriguing that you might delay progression of brain metastases with tucatinib that clearly has efficacy in the brain.  So, I think that this is a hugely exciting advance for our patients, and these approaches are quickly moving into the early stage setting. T-DXd compared to standard chemo, essentially followed by THP, so a sequenced approach resulted in more pathologic complete responses than a standard THP-AC-type neoadjuvant therapy. T-DXd alone for eight cycles wasn't better, and that's interesting. We still need the sequenced non-cross-resistant chemo. But I think even more importantly, the data from DESTINY-Breast05 looking at T-DXd versus T-DM1 in patients with residual disease after neoadjuvant HER2-targeted therapy showed a remarkable improvement in invasive disease-free survival with T-DXd versus T-DM1, and quite early. It was a high-risk population, higher risk than the T-DM1 trial with KATHERINE, but earlier readout with a remarkable improvement in outcome. We expect to be FDA approved sometime in the first half of 2026. So then we'll get patients who've already had T-DXd who get metastatic disease. But my hope is that with T-DXd, maybe with tucatinib in the right group of patients or even sequenced in very high-risk disease, that we could cure many more patients with early-stage HER2-positive breast cancer and cure a subset, a greater subset of patients with de novo metastatic disease. Dr. Monty Pal: That's brilliant. And you tackled so many questions that I was going to follow up with there: brain metastases, etc. That was sort of looming in my mind. I mean, general thoughts on an ADC versus a TKI in the context of brain mets? Dr. Hope Rugo: Yeah, it's an interesting question because T-DXd has shown quite good efficacy in this setting. And tucatinib, of course, had a trial where they took patients with new brain mets, so a larger population than we've seen yet for the T-DXd trials, and saw that not only did they delay progression of brain metastases and result in shrinkage of existing untreated brain mets, but that patients who develop a new brain met, they could stay on the same assigned treatment. They got stereotactic radiation, and then the patients who were on tucatinib with trastuzumab and capecitabine had a further delay in progression of brain mets compared to those on the placebo arm, even after treatment of a new one that developed on treatment. So, I think it's hard. I think most of us for a lot of brain mets might start with the tucatinib approach, but T-DXd is also a very important treatment. You know, you're kind of trading off a diarrhea, some liver enzyme elevations with tucatinib versus nausea, which you really have to work on managing because it can be long-delayed nausea, and this risk of ILD, interstitial lung disease, that's about 12%, with most but not all trials showing a mortality rate from interstitial lung disease of just under 1 percent. In the early-stage setting, it was really interesting to see that with T-DXd getting four cycles in the neoadjuvant setting, a lot less ILD noted than the patients who got up to 14 cycles, as I think they got a median of 10 cycles in the post-surgical setting, there was a little bit more ILD. But I think we're going to be better and better at finding this earlier and preventing mortality by just stopping drug and treating earlier with steroids. Dr. Monty Pal: And this ILD issue, it always seems to resurface. There are drugs that I use in my kidney cancer clinic, everolimus, common to perhaps the breast cancer clinic as well, pembrolizumab, where I think the pattern of pneumonitis is quite different, right? What is your strategy for recognizing pneumonitis early in this context? Dr. Hope Rugo: Well, it is, and you know, having done the very early studies in everolimus where we gave it in the neoadjuvant setting and we're like, "Hmm, the patient came in with a cough. What's going on?" You know, we didn't know. And you have mouth sores, you know, we were learning about the drug as we were giving it. What we don't do with everolimus and CDK4/6 inhibitors, for example, is grade 1 changes like radiation pneumonitis, we don't stop, we don't treat it. We only treat for symptoms. But because of the mortality associated with T-DXd, albeit small, we stop drug for grade 1 imaging-only asymptomatic pneumonitis, and some of us treat with a half dose of steroids just to try and hasten recovery. We've actually now published or presented a couple of datasets from trials, a pooled analysis and a real-world analysis, that have looked at patients who were retreated after grade 1 pneumonitis or ILD and tolerated drug very well and none of them died of interstitial lung disease, which was really great to see because you can retreat safely and some of these patients stayed on for almost a year benefiting from treatment. So, there's a differential toxicity profile with these drugs and there are risk factors which clearly have identified those at higher risk: prior ILD, for example. A French group said smoking; other people haven't found that, maybe because they smoked more in France, I don't know. And being of Japanese descent is quite interesting. The studies just captured that you were treated in Japan, but I think it's probably being of Japanese descent with many drugs that increases your risk of ILD. And, you know, older patients, people who have hypoxia, those are the patients. So, how do we do this? With everolimus, we don't have specific monitoring. But for T-DXd we do; we do every nine weeks to start with and then every 12 weeks CT scans because most of the events occur relatively early. Somebody who's older and at higher risk now get the first CT at six weeks. Dr. Monty Pal: This is super helpful. And I have to tell you, a lot of these drugs are permeating the bladder cancer space which, you know, is ultimately going to be a component of my practice, so thank you for all this. We could probably stay on this topic of HER2-positive disease forever. I'm super interested in that space still. But let me shift gears a little bit and talk about triple-negative breast cancer and this evolving space of HR-positive, HER2-low breast cancer. I mean, tell us about ADCs in that very sort of other broad area. Dr. Hope Rugo: So triple-negative disease is the absolute hardest subset of disease that we have to treat because if you don't have a great response in the early stage setting, the median survival is very short, you know, under two years for the majority of TNBCs, with the exception of the small percentage of low proliferative disease subsets. The co-question is what do we do for these patients and how do we improve outcome? And sacituzumab govitecan has been one strategy in the later line setting that was shown to improve progression-free and overall survival, the Trop-2 ADC. We had recently three trials presented with the two ADCs, sacituzumab govitecan and the other Trop-2 ADC that's approved for HR-positive disease, datopotamab deruxtecan. And they were studied in the first-line setting. Two trials with SG, sacituzumab govitecan, those trials, one was PD-L1 positive, ASCENT-04. That showed that SG with a checkpoint inhibitor was superior, so pembrolizumab was superior to the standard KEYNOTE-355 type of treatment with either a taxane or gemcitabine and carboplatin with pembrolizumab for patients who have a combined positive score for PD-L1, 10 or greater. So, these are patients who are eligible for a checkpoint inhibitor, and SG resulted in an improved progression-free survival.  The interesting thing about that dataset is that few patients had received adjuvant or neoadjuvant checkpoint inhibitor, which is fascinating because we give it to everybody now. But access is an issue and timing of the study enrollment was an issue. The other thing which I think we've all really applauded Gilead for is that there was automatic crossover. So, you could get from the company, to try and overcome some of the enormous disparities worldwide in access to these life-saving drugs, you could get SG through the company for free once you had blinded independent central review confirmation of disease progression. Now, a lot of the people who got the SG got it through their insurance, they didn't bill the company, but 80 percent of patients in the control arm received SG in the second-line setting. So that impacts your ability to look at overall survival, but it's an incredibly important component of these trials. So then at ESMO, we saw the data from SG and Dato-DXd in the first-line metastatic setting for patients who either had PD-L1-negative disease or weren't eligible for an immunotherapy. For the Dato study, TROPION-Breast02, that was 10 percent of the patients who had PD-L1-positive disease but didn't get a checkpoint inhibitor, and for the ASCENT-03 trial population it was only 1 percent. Importantly, the trials allowed patients who relapsed within a year of receiving their treatment with curative intent, and the Dato study, TB-02, allowed patients who relapsed while on treatment or within the first six months, and that was 15 percent of the 20 percent of early relapsers. The ASCENT trial, ASCENT-03, had 20 percent who relapsed between 6 and 12 months. The drugs were better than standard of care chemotherapy, the ADCs in both trials, which is very nice. Different toxicity profiles, different dosing intervals, but better than standard of care chemotherapy in the disease that's hardest for us to treat. And importantly, when you looked at the subset of early relapsers, those patients also did better with the ADC versus chemotherapy, which is incredibly important. And we were really interested in that 15 percent of patients who had early relapse. I actually think that six months thing was totally contrived, invented, you know, categorization and doesn't make any sense, and we should drop it. But the early relapsers were 15 percent of TB-02 and Dato was superior to standard of care chemo. We like survival, but the ASCENT trial again allowed the crossover to an approved ADC that improved survival and 80 percent of patients crossed over. In the Dato trial, they did not allow crossover, they didn't provide Dato, which isn't approved for TNBC but is for HR-positive disease, and they didn't allow, of course, pay for SG. So very few patients actually crossed over in their post-treatment data and in that study, they were able to show a survival benefit. So actually, I think in the U.S. where we can use approved drugs already before there's a fixed FDA approval, that people are already switching to use SG or Dato in the first-line setting for metastatic TNBC that's both PD-L1 positive for SG and PD-L1 negative for both drugs. And I think understanding the toxicity profiles of the two drugs is really important as well as the dosing interval to try and figure out which drug to use. Dr. Monty Pal: Brilliant. Brilliant. Well, I'm going to shift gears a little bit. ADCs are a topic, again, just like HER2-positive disease we could stay on forever. Dr. Hope Rugo: Huge. Yes. Dr. Monty Pal: But we're going to shift gears to another massive topic, which is oral SERDs. In broad strokes, right, this utilization of CDK4/6 inhibitors in the context of HR-positive breast cancer is obviously, you know, a paradigm that's been well established at this point. Where do we sequence in oral SERDs? Where do they fit into this paradigm? Dr. Hope Rugo: Ha! This is a rapidly changing area; we keep changing what we're saying every other minute. And I think that there are three areas of great interest. So one is patients who develop ESR1 mutations that allow constitutive signaling through the estrogen receptor, even when there's not estrogen around, and that is a really important mutation that is subclonal; it develops under the pressure of treatment in about 40 percent of patients. And it doesn't happen when you first walk in the door. And what we've seen is that oral SERDs as single agents are better than standard single-agent endocrine therapy in that setting. The problem that we've had with that approach is that we're now really interested in giving targeted agents with our endocrine therapies, not just in the first-line setting where CDK4/6 inhibitors are our standard of care with survival benefit for ribociclib and, you know, survival benefit in subsets with other CDK4/6 inhibitors, and abemaciclib with a numeric improvement. So we give it first line. The question is, what do you do in the second-line setting? Because of the recent data, we now believe that oral SERDs should be really given with a targeted agent. And some datasets which were recently presented, which I think have helped us with that, have been EMBER-3 and then the most recently evERA BC, or evERA Breast Cancer, that looked at the oral SERD giredestrant with everolimus compared to standard of care endocrine therapy with everolimus, where 100 percent of patients received prior CDK4/6 inhibitor and showed a marked improvement in progression-free survival, including in the subsets of patients with a short response, 6-12 months of prior response to CDK4/6 inhibitor and in those who had a PIK3CA pathway mutation. The thing is that the benefit looks like it's much bigger in the ESR1 mutant population, although response was better, PFS wasn't better in the wild type. So, we're still trying to figure that out. We also saw EMBER-3 with imlunestrant and abemaciclib as a second line. Not everybody had had a prior CDK4/6 inhibitor; they compared it to imlunestrant alone, but still the data was quite striking and seemed to cross the need for ESR1 mutations. And then lastly, we saw data from the single arms of the ELEVATE trial looking at elacestrant with everolimus and abemaciclib and showed these really marked progression-free survival data, even though single-arm, that crossed the mutation status. At least for the everolimus combination, abemaciclib analysis is still to come in the mutated subgroups. But really remarkable PFS, much longer.  Single-agent fulvestrant after CDK4/6 inhibitor AI has a PFS in like the three-month range and in some studies, maybe close to five months. These are all at 10-plus months and really looking very good. And so those questions are, is it ESR1 mutation alone? Is it all comers? We'd like all comers, right? We believe in the combination approach and we're learning more about combinations with drugs like capivasertib and other drugs as we move forward. Everybody now wants to combine their targeted agent with an oral SERD because they're clearly here to stay with quite remarkable data. The other issue, so the second issue in the metastatic setting is, does it make a difference if we change to an oral SERD before radiographic imaging evidence of progression? And that was the question asked in the SERENA-6 trial where patients had serial monitoring for the presence of ESR1 mutations in ctDNA. And those who had them without progression on imaging could be randomized to switch to camizestrant with the same CDK4/6 inhibitor or stay on their same AI CDK4/6 inhibitor. And they showed a difference in progression-free survival that markedly favored camizestrant. But interestingly, the people who were on the standard control arm had an ESR1 mutation, we think AIs don't work, they stayed on for nine more months. The patients who were on the camizestrant stayed on for more than 16 months. And they presented some additional subset data which showed the same thing: follow-up PFS data, PFS2, all beneficial in SERENA-6 at the San Antonio [Breast Cancer Symposium]. So, we're still a little bit unclear about that. They did quality of life, and pain was markedly improved. They had a marked delayed time to progression of pain in the camizestrant arm. So this is all a work in progress, trying to understand who should we switch without progression to an oral SERD based on this development of this mutation that correlates with resistance. And, you know, it's interesting because the median time to having a mutation was 18 months and the median time to switch was almost 24 months. And then there were like more than 3,000 patients who hadn't gotten a mutation, hadn't switched, and were still okay. So screening everybody is the big question, and when you would start and who you would change on and how this affects outcome. Patients didn't have access to camizestrant in the control arm, something we can't fix but we have experimental drugs. We're actually planning a trial, I hope in collaboration with the French group Unicancer, and looking at this exact question. You know, if you switch and you change the CDK4/6 inhibitor and then you also allow crossover, what will we see? Dr. Monty Pal: We're coming right to the tail end of our time here, and I could probably go on for another couple of hours with you here. But if you could just give us maybe one or two big highlights from San Antonio, any thoughts to leave our audience with here based on this recent meeting? Dr. Hope Rugo: Yeah, I mean, I talked about a lot of those new data already from San Antonio, and the one that I'd really like to mention which I think was, you know, there were a lot of great presentations including personalized screening presented from the WISDOM trial by my colleague Laura Esserman, fascinating and really a big advance. But lidERA was the big highlight, I think, outside of the HER2CLIMB-05 which I talked about earlier in HER2-positive disease. And this study looked at giredestrant, the oral SERD versus standard of care endocrine therapy as treatment for medium and high-risk early-stage breast cancer. And what they showed, which I think was really remarkable with just about a three-year median follow-up, was an improvement in invasive disease-free survival with a hazard ratio of 0.7. I mean, really quite remarkable and so early. It looked as though this was all driven by the high-risk group, which makes sense, not the medium risk, it's too early. And also that there was a bigger benefit in patients who were on tamoxifen compared to giredestrant versus AI, but for both groups, the confidence intervals didn't cross 1. There's even a trend towards overall survival, even though it's way too early. I think that, you know, really well-tolerated oral drug that could improve outcome in early-stage disease, this is the first advance we've seen in over two decades in the treatment of early-stage hormone receptor-positive disease with just endocrine therapy. I think we think that we don't want to give up CDK4/6 inhibitors because we saw a survival benefit with abemaciclib and a trend with giving ribociclib in the NATALEE trial. So we're thinking that maybe one approach would be to give CDK4/6 inhibitors and then switch to an oral SERD or to have enough data to be able to give oral SERDs with these CDK4/6 inhibitors for early-stage disease. And that's all in the works, you know, lots of studies going on. We're going to see a lot of data with both switching 8,000 patients with an imlunestrant switching trial, an elacestrant trial going on, and safety data with giredestrant with abemaciclib and soon to come ribociclib. So, this is going to change everything for the treatment of early-stage breast cancer, and I hope cure more patients of the most common subset of the most common cancer diagnosed in women worldwide. Dr. Monty Pal: Super exciting. It's just remarkable to hear how this has evolved since 25 years ago, which is really the last time I sort of dabbled in breast cancer.  Thank you so much, Hope, for joining us today. These were fantastic insights. Appreciate you being on the ASCO Daily News Podcast and really want to thank you personally for your remarkable contribution to the field of breast cancer. Dr. Hope Rugo: Thank you very much, and thanks for talking with me today. Dr. Monty Pal: You got it. And thanks a lot to our listeners today as well. You'll find links to all the studies we discussed today in the transcript of this episode. Finally, if you value the insights that you hear today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Monty Pal @montypal Dr. Hope Rugo   @hoperugo Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  

This Thrivecast episode, the final one of 2025, features a solo conversation led by Jason, who reflects on seasons of change and intentional leadership as he looks ahead to 2026. Drawing on nearly 25 years of firm ownership and 15 years of leading Thriveal, Jason explores how change—whether chosen or forced—can become a catalyst for growth when approached strategically. He shares personal insights on how markets evolve, teams shift, and leaders must continually reassess where they are most needed and what they are truly committed to building.Jason outlines a significant pivot within his accounting firm, which is broadening its long-standing niche focus to serve entrepreneurs more generally after recognizing major shifts and challenges within its previous target market. Rather than waiting for disruption to dictate the next move, he explains why proactively adapting alongside the market is essential. That same philosophy is being applied to Thriveal, which is entering a new season after 15 years of operating as a broad, open community for firm owners around the world.Looking ahead, Jason explains how Thriveal is choosing depth over scale by narrowing its focus and restructuring into two core programs designed specifically for growing and scaling firms. The Venture program serves firm owners with five or more team members, while the Ascent program supports firms generating one million dollars or more in revenue. By limiting enrollment and moving away from multiple community membership levels, Thriveal is creating a more intimate, high-commitment environment where firm owners receive consistent accountability, coaching, and peer connection throughout the year.The episode also details several intentional changes that support this deeper focus, including sunsetting the Deeper Weekend conference, reshaping master classes, expanding self-paced courses, and developing future workshops connected to the newly released book Scale with Purpose. Throughout the episode, Jason encourages listeners to view change as a core leadership responsibility—one that requires courage, clarity, and a willingness to let go of what is familiar in order to build something more meaningful. The conversation closes with an invitation to firm owners who feel ready for this next season to explore whether Thriveal's Venture or Ascent programs are the right fit for their growth in 2026.

DEEP SPACE NINE returns to RANDOM ‘SODE with Season 5's “The Ascent” & then we continue with The Nacelle Company's Excellent TREK documentary THE CENTER SEAT. Drop us a line at secretfriendsunite@gmail.com and let us know what you're enjoying in the ‘world of nerd' and we might feature your comments on the show! News from TREKMOVIE.COM Star Trek 60 is upon us - what can we expect in 2026?But Chekov Still a Mystery -Sulu and McCoy join the end of SNWOur Patreon Producers are John Sadorf, Corey in HD, Kurt Krug , Tawnya Lee, ChipotleBear, Famous Seamus, Cam The Movie Man, JNewport007, Prozac Man aka Darth Prozac and FR8 ConductorGet 50% off your first month at Patreon.com/secretfriendsuniteFind us online at secretfriendsunite.com for ALL of our episodes, additional content and bios of our SFU Network stars!Hear Peter on STARSHIP EXCELSIOR at https://starshipexcelsior.com/episodes/#s6Check out Youtube for all our video contentSubscribe to our podcasts on Apple and SpotifyHit us up on Threads, Instagram & BlueSky: @Secret.Friends.Unite, @Secretfriendsunite, @TheCeeThreeLet us know what you're enjoying in the TREK world!Check out our LinkTree for all the ways to reach usGet all your SECRET FRIENDS UNITE merch at our Redbubble store! Click here

NADAR'S BALLOON AND THE BIRTH OF PHOTOGRAPHY Colleague Anika Burgess, Flashes of Brilliance. In 1863, the photographer Nadar undertook a perilous ascent in a giant balloon to fund experiments for heavier-than-air flight, illustrating the adventurous spirit required of early photographers. This era began with Daguerre's 1839 introduction of the daguerreotype, a process involving highly dangerous chemicals like mercury and iodine to create unique, mirror-like images on copper plates. Pioneers risked their lives using explosive materials to capture reality with unprecedented clarity and permanence. NUMBER 1 1870 siege of the Paris Commune.

Well, now that THAT's over with (THAT being the year 2025), it's time to see what we're looking forward to in 2026. A list made of our hopes and dreams for the new year, shared with all of our beloved listeners. We've discovered Frank's weakness. (It's Mothra.) Brian really loves early-stage concept art. Frank reveals Mike's perfect game - a Legacy game comprised entirely of stickers. "When in doubt, kill a Nazi." Not a board game, but a fun set of puzzles for people who like word searches that quickly get out of hand. What are you looking forward to playing in 2026? What are we overlooking? Come visit our Discord server to chat with us and other like-minded game nerds! As always, thank you for listening. Please consider writing us an iTunes review if you like what you hear! We'd also love to have you visit our website and let us know what kinds of games we should discuss next. You're also more than welcome to comment on the episode page, or our Discord, or our Facebook page, or tag @ascentofboardgames on Bluesky. Whatever way you prefer to share your opinions with us, we'd love to hear them.  As always, we appreciate your listening - stay safe out there, and happy gaming! Website: https://www.ascentofboardgames.com Email: ascentofboardgames@gmail.com Discord: https://discord.gg/tdH3QAn  Facebook: https://www.facebook.com/groups/ascentboardgames/ Bluesky: https://bsky.app/profile/ascentofboardgames.bsky.social Discord: http://discord.ascentofboardgames.com Instagram: https://www.instagram.com/ascentofboardgames/ And, very occasionally, Twitch: https://www.twitch.tv/ascentofboardgames Intro and outro music is "Evening Melodrama" by Kevin MacLeod (incompetech.com), licensed under a Creative Commons: By Attribution 3.0 License. The Ascent of Board Games is licensed under a Creative Commons Attribution 4.0 International License. Some rights reserved. Thank you for listening!

These fifteen Psalms of Ascent, sung by ancient pilgrims journeying to Jerusalem for the annual feasts, form a theological journey from exile to worship, reflecting the spiritual pilgrimage of God's people. Beginning in distress and dispersion—symbolized by the distant lands of Meshech and Kedar—they move through themes of divine defense, longing for God's presence, and dependence on His mercy, culminating in the arrival at Zion, where God's blessings are experienced in peace, perseverance, pardon, and profound unity. Each Psalm unfolds a facet of God's redemptive work: from the protection of the Lord who never slumbers, to the restoration of joy after sorrow, the assurance that true success comes only through divine blessing, and the ultimate joy of worshiping the Creator, who dwells among His people. The journey concludes not in a temple of stone, but in the eternal reality of God's presence, where His people, united in Christ, praise Him forever, knowing that all good things flow from the Lord, maker of heaven and earth.

A reading of reflections and poems of Saint Symeon taken from various sources and translations including:~ The Book of Mystical Chapters: Meditations on the Soul's Ascent from the Desert Fathers and Other Early Christian Contemplatives, Translated by John Anthony McGuckin~ The Enlightened Heart: An Anthology of Sacred Poetry, by Stephen Mitchell~ The Fire rises in Me - English version by Ivan M. GrangerSaint Symeon the New Theologian (949 -1022 AD) was an Eastern Orthodox monk and poet who was one of the three saints canonized by the Eastern Orthodox Church and given the title of "Theologian." "Theologian" was not applied to Symeon in the modern academic sense of theological study; the title was intended only to recognise someone who spoke from personal experience of the vision of God. One of his principal teachings was that humans could and should experience theoria (literally "contemplation," or direct experience of God).Symeon was born into the Byzantine nobility and given a traditional education. At age fourteen, he met Symeon the Studite, a renowned monk of the Monastery of Stoudios in Constantinople, who convinced him to give his own life to prayer and asceticism under the elder Symeon's guidance. By the time he was thirty, Symeon the New Theologian became the abbot of the Monastery of Saint Mamas, a position he held for twenty-five years. He attracted many monks and clergy with his reputation for sanctity, though his teachings brought him into conflict with church authorities, who would eventually send him into exile. Symeon is recognized as the first Eastern Christian mystic to share his own mystical experiences freely. Some of his writings are included in the Philokalia, a collection of texts by early Christian mystics on contemplative prayer and hesychast teachings. Symeon wrote and spoke frequently about the importance of experiencing directly the grace of God, often talking about his own experiences of God as divine light. Another common subject in his writings was the need of putting oneself under the guidance of a spiritual father. The authority for many of his teachings derived from the traditions of the Desert Fathers, early Christian monks and ascetics. Symeon's writings include Hymns of Divine Love, Ethical Discourses, and The Catechetical Discourses.Photography: George Digalakis ~ The Sound of Silence  / georgedigalakisphotography  https://www.digalakisphotography.com/Music: "Let My Love Be Heard" by Jake Runestad. Performed by the Bob Cole Conservatory Chamber Choir.   • Let My Love Be Heard - Jake Runestad  Cousin Silas - Slow Rotations https://cousinsilas1.bandcamp.com/With thanks to Pat for his kind permission to use his music for this channel.

From Ashes to Ascent “A Story of Strength, Survival, and Unshakeable Hope”: Volume I Born to Fight and Win! by Amy Granit https://www.amazon.com/Ashes-Ascent-Strength-Survival-Unshakeable/dp/1326371096 VOLUME I “Born to Fight and Win!”A child of war. A mother's pain. A daughter's courage. Volume I of From Ashes to Ascent reveals Mara's earliest years—years shaped by the shadows of World War II and the unforgiving realities of a devastated Soviet Union. Born as bombs fell and fathers disappeared, Mara grows up in poverty-stricken barracks, surrounded by hunger, cold, and cruelty. Her mother, broken by grief and loss, becomes both caregiver and tormentor—leaving Mara to navigate a childhood marked by fear, confusion, and emotional isolation. Yet beneath her frail exterior lives a fighter. Whether standing up to her mother's violence, facing the brutal cold of Kazakhstan winters, or carving out moments of joy amid deprivation, Mara discovers her inner strength long before she understands its meaning. In this gripping and emotional first volume, Amy Granit paints a vivid portrait of a girl growing up in a world where survival is an act of defiance—and hope is a victory in itself. Themes: • Post-war trauma • Childhood resilience • Soviet history & village life • Abuse, healing, and identity • The will to rise above one's circumstances

Welcome to the Oncology Brothers podcast! In this episode, we dived into the key highlights from the SABCS 2025 conference, focusing on metastatic hormone receptor-positive breast cancer. Join us as we discussed: • The role of CDK4-6 inhibitors in frontline therapy, featuring updates from the AMBRE and MONALEESA-3 studies • Insights into second-line treatment options, including the VIKTORIA-1, evERA, EMBER-3, SERENA-6 trials • A critical look at the ASCENT-07 study, exploring the role of antibody-drug conjugates (ADCs) in endocrine-resistant disease We were thrilled to have Dr. Hope Rugo, a world-renowned breast medical oncologist from City of Hope, share her expertise and insights on these pivotal studies. Tune in for an informative discussion that unpacks the latest advancements in treatment options for metastatic hormone receptor-positive breast cancer, and learn how these findings may impact clinical practice. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, recent approvals, and conference highlights! #SABCS2025 #MBC #HRpositive #CDK46 #ADCs #OncologyBrothers

Have a Social with the Saints! Receive encouragement for your daily life as we meet & discuss this chain-smoking misfit who became a heroic martyr during the Second World War. Who was she? Be encouraged and inspired in your daily life! Get a free quote card and pamphlet of Bl Sára Salkaházi here. We invite you to share them with friends and family. We want to hear from you! What struck you about Bl Sára Salkaházi? Please send us your feedback to join the conversation by email at ministry@pilgrimcenterofhope.org The official Socials with the Saints theme song is "Hero's Ascent" by Chris Haugen. Used with permission. Thanks for listening, and remember, you are never alone in the communion of the saints! May God bless you. Help us spread hope!

Today on Ascend: The Great Books Podcast, Dcn. Harrison Garlick, Dr. Tiffany Schubert of Wyoming Catholic College, George of the Chivalry Guild, and Banished Kent discuss Fitts 2 and 3 of Sir Gawain and the Green Knight!Visit thegreatbookspodcast.com for our reading schedule!Check out our 50 QUESTION-AND-ANSWER GUIDE to Sir Gawain and the Green Knight.Be sure to visit our sister publication, THE ASCENT, for Christian spirituality.Episode SummaryThe panel continues the Christmas reading of Sir Gawain and the Green Knight, exploring Fitts 2 and 3 with Dr. Tiffany Schubert. The discussion covers the meditative passage of time, Gawain's elaborate armor and pentangle, his wilderness journey, arrival at the lord's castle, and the three bedroom temptations mirroring the lord's hunts. Themes of courtesy versus Christian prudence, the unexpected location of peril, and human imperfection dominate.Why Sir Gawain and the Green Knight Is Worth ReadingThis poem masterfully redirects chivalric expectations from martial heroism to internal trials of temperance and fidelity, using irony, humor, and subtle symbolism to expose the tensions within knighthood itself. As Dr. Schubert notes, it brings readers “back down into this world”—a murky, incarnate place of comfort and laughter where true danger often hides—while probing whether Christian virtue can govern or perfect courtly ideals. Rich in liturgical resonance, Marian devotion, and realistic grace, it humanizes the heroic quest, making it profoundly relevant for reflecting on temptation, fear, and humility during the Christmas season.Key Discussion PointsTime & Seasons: Opening meditation on cyclical yet forward-moving time; Gawain's lingering and All Hallows' departure as liturgical reflection on mortality.Armor & Pentangle: Lavish buildup of Gawain's gear and “endless knot” (five sets of five perfections, piety surpassing all) as outward ideal—quickly deflated as armor is removed.Mary Inside the Shield: Hidden source of strength and piety governing the public projection of perfection.Wilderness to Castle: Dismissal of monster battles; castle as surprising “answer” to Marian prayer—Providence working through murky, tempting paths.Second Christmas Game: Bertilak's exchange of winnings parallels the first deadly game, shifting peril to courtesy and domestic temptation.Three Temptations & Hunts: Parallel structure—doe (subtle), boar (fierce), fox (cunning); Gawain resists lust admirably but accepts/conceals girdle out of fear of death.Courtesy vs. Christian Prudence: Repeated bedroom returns (no Joseph-like flight) prolong exposure, allowing lady to exploit deeper flaw—courtesy overriding removal from sin.Confession Ambiguity: Post-girdle absolution raises questions of self-awareness and lingering human frailty.

Welcome to Behold the King: Christmas with Ascent. Today as we celebrate the birth of Jesus, we challenge you to see the story of Christmas and the ultimate gift in a new way. Let's tune in and listen.Connect with us: @ascentchurchvaConnect with our Lead Pastor: @pastor.tlaneIf you've just made a decision for Christ, we'd love to celebrate with you. Please connect with us through our A-Card here: https://www.liinks.co/ascentchurch 

Shot of Nostalgia: The SmackDown Six Era rolls on with your host Acefield Retro, and this week we're stepping into one of the heaviest, most emotionally loaded chapters of the whole project. Episode 7: The Legacy Run covers January through March 2004 — the stretch where the SmackDown Six philosophy stops being "just" a great TV formula and becomes the backbone of WWE's entire main-event scene. Chris Benoit and Eddie Guerrero, the two workhorses who defined this era between the ropes, finally break through the ceiling and hit the very top of the industry at the exact same time. We start at the 2004 Royal Rumble, a one-match show that actually delivers exactly what WWE needed. Paul Heyman stacks the deck, forces Benoit into the #1 slot, and dares him to fail. Instead, Benoit puts together a marathon performance: 61 minutes, six eliminations, and a finish built around pure will, dragging Big Show over the top rope in a head-and-arm choke that feels earned instead of cute. Along the way we hit all the key beats that made this Rumble feel alive in the building — Orton's elevation through the Foley feud, Goldberg getting robbed by Brock, Big Show as a real "final boss," and the sense that for once, the obvious story actually got the right payoff. From there, we turn to No Way Out 2004, where Eddie Guerrero walks into San Francisco with three weeks of build… and a lifetime of baggage. We walk through how a thrown-together title program becomes a full redemption story: the SmackDown Rumble that sends Eddie to the title shot, the promo duel where Brock mocks his addictions and Eddie weaponizes his own past, and the infamous mariachi "celebration" that starts as comedy and turns into something dead serious. Then we break down the match itself as a heavyweight title fight built on structure and psychology — Brock's 2002 monster template, Eddie chopping down the base, the STF that flips the crowd from hopeful to believing, Goldberg's spear that protects the champion without stealing Eddie's moment, and the DDT-onto-the-belt into Frog Splash finish that still plays as one of the most cathartic three-counts WWE has ever produced. After that, we head to Madison Square Garden for WrestleMania XX, where the World Heavyweight Championship closes the show for the very first time. We don't ignore the reality of Benoit's crimes or how impossible it is to watch his work the same way after 2007 — that context lives with this match forever. But we also walk honestly through what this main event represented in 2004: the SmackDown Six template blown up to world-title scale. We dig into how the triple threat with Triple H and Shawn Michaels turns a format that usually feels cheap into a 24-minute clinic — the "Let's Go Benoit" crowd, the rotating pairings, the Crossface spot where Hunter literally grabs Shawn's hand to stop the tap, the table bump that buys time for the final act, and the visual of Triple H tapping clean in the middle of MSG. It's the one time in that era where the finish matches the story they told for months. We keep rolling with Eddie Guerrero vs. Kurt Angle from that same night — maybe the most "pure SmackDown" match on the card. This is where we zoom in on everything that made Eddie special at this stage of his career: the improvisation, the timing, the creativity that compensated for a body that had taken way too much punishment. Angle tries to strip the magic away and turn it into a straight amateur wrestling lesson — grinding holds, targeted rib and ankle work, suplexes on a loop — and for most of the match, he succeeds. Eddie's comeback isn't about overpowering him; it's about surviving just long enough to create one opening. We break down the boot spot in detail, why it works as psychology instead of a cheap gag, and how that final small package stacks up as the perfect "lie, cheat, steal" finish without burying Angle for a second. And then we close with the image that defined this era at the time: confetti falling in Madison Square Garden as Eddie Guerrero and Chris Benoit celebrate together, both holding world titles, both representing a version of WWE where skill and heart could overcome size and politics. Today that shot is complicated, even haunting, because of what would happen in the years that followed — Eddie's death, Benoit's actions. We sit in that discomfort instead of pretending it isn't there, but we also talk about what that night meant in 2004 for fans who had lived through the entire arc of the SmackDown Six: the B-show workhorses finally standing on top of the company they had quietly carried. By the time we're done with early 2004, the SmackDown Six era isn't just about a tag formula or a handful of TV classics. It's a storytelling blueprint — athletic, grounded, character-driven — that bleeds into both brands, reshapes what a WWE main event can look like, and influences everything from peak-era NXT to how AEW builds its big match payoffs today. Shot of Nostalgia: The SmackDown Six Era Episode 7 — The Legacy Run — premieres Saturday, December 13, 2025, wherever you listen. Like, subscribe, and leave a review to help the show grow. Visit TurnbuckleTavern.com for merch, archives, and the full network schedule, and support the project at Patreon.com/TheTurnbuckleTavern for just $2.99 a month to help keep these deep dives going. Powered by G FUEL and Dick Lazers — use code TAVERN at checkout for 20% off your entire order.  

The final stages of the expedition to summit Denali were grueling for Walter Harper and the rest of the team. And after that accomplishment, Harper's life was tragically short. Research: Bishop, Click. “Sponsor Statement SB-144 – Walter Harper Day.” Alaska State Legislature. https://www.akleg.gov/basis/get_documents.asp?session=31&docid=58198 Dean, Patrick. “How Hudson Stuck's Ascent of Denali Boosted Recognition of Indigenous Alaskans.” History News Network. 12/13/2020. https://www.hnn.us/article/how-hudson-stucks-ascent-of-denali-boosted-recogni Denali National Park and Preserve. “Superintendent Harry Karstens.” https://www.nps.gov/dena/learn/photosmultimedia/station06a.htm Ehrlander, Mary. “Walter Harper, Alaska Native Son.” UAF Summer Sessions & Lifelong Learning. Via YouTube. 7/7/2018. https://www.youtube.com/watch?v=9-FrvS3gONg Farquhar, Francis P. “Henry P. Karstens—1878-1955.” The American Alpine Club. https://publications.americanalpineclub.org/articles/12195611200/Henry-P-Karstens-1878-1955 Hayes, Alan L. “One Congregation, Two Cultures: St. Mark’s Episcopal Church Nenana, Alaska.” Anglican and Episcopal History, vol. 68, no. 1, 1999, pp. 141–46. JSTOR, http://www.jstor.org/stable/42612013. Accessed 24 Nov. 2025. James, David A. “In story of the legendary ‘Walter Harper: Alaska Native Son,’ Denali is just the beginning.” Alaska Daily News. 12/16/2017. https://www.adn.com/arts/books/2017/12/16/in-story-of-the-legendary-walter-harper-alaska-native-son-denali-is-just-the-beginning/ James, David. “The Brief, But Bright Story of Walter Harper.” Alaska. 5/21/2022. https://alaskamagazine.com/authentic-alaska/the-brief-but-bright-story-of-walter-harper/ John, Peter. “The Gospel According to Peter John.” Krupa, David J., editor. Alaska Native Knowledge Network. 1996. https://ankn.uaf.edu/publications/Books/Peter_John.pdf Johnson, Erik. “Honoring the Unsung Heroes of the 1913 Summit Expedition: Esaias George and John Fredson.” National Park Service. https://www.nps.gov/articles/000/dena-history-unsung-heroes.htm Johnson, Erik. “The Ultimate Triumph and Tragedy: Remembering Walter Harper 100 Years Later.” National Park Service. Denali National Park. https://www.nps.gov/articles/dena-history-harper.htm Manville, Julie and Ross Maller. “The Influence of Christian Missionaries on Alaskan Indigenous Peoples.” Interdisciplinary Journal of Research on Religion. Vol. 5, Article 8. 2009. Miller, Matt. “‘May Light Perpetual Shine Upon Them.’” KTOO. https://www.ktoo.org/2013/10/26/may-light-perpetual-shine-upon-them/ New York Times. “Yukon Indian Opens Coney Island Eyes.” 6/1/1914. Stuck, Hudson. “A winter circuit of our Arctic coast; a narrative of a journey with dog-sleds around the entire Arctic coast of Alaska.” New York. C. Scribner’s Sons. 1920. https://archive.org/details/wintercircuito00stuc/ Stuck, Hudson. “Ten Thousand Miles With A Dog Sled a Narrative of winter travel in Interior Alaska.” 1917. https://archive.org/details/tenthousandmiles0000huds/ Stuck, Hudson. “The ascent of Denali (Mount McKinley) a narrative of the first complete ascent of the highest peak in North America.” New York, C. Scribner's Sons. 1914. https://archive.org/details/ascentofdenalimo01stuc/ Stuck, Hudson. “Voyages on the Yukon and its tributaries: a narrative of summer travel in the interior of Alaska.” New York : Charles Scribner's Sons. 1917. https://archive.org/details/cihm_76545/ Walker, Tom. “A Brief Account of the 1913 Climb of Mount McKinley.” Denali National Park and Preserve. https://www.nps.gov/dena/learn/historyculture/1913ex.htm Woodside, Christine. “Who Led the First Ascent of Denali? Hudson Stuck, Archdeacon of the Yukon.” Vol. 63, No., 2 Summer/Fall 2012. See omnystudio.com/listener for privacy information.

While working as a guide in his youth, Walter Harper met and worked for a man named Hudson Stuck. Their friendship would lead to Walter becoming the first person to reach the summit of Denali. Research: Bishop, Click. “Sponsor Statement SB-144 – Walter Harper Day.” Alaska State Legislature. https://www.akleg.gov/basis/get_documents.asp?session=31&docid=58198 Dean, Patrick. “How Hudson Stuck's Ascent of Denali Boosted Recognition of Indigenous Alaskans.” History News Network. 12/13/2020. https://www.hnn.us/article/how-hudson-stucks-ascent-of-denali-boosted-recogni Denali National Park and Preserve. “Superintendent Harry Karstens.” https://www.nps.gov/dena/learn/photosmultimedia/station06a.htm Ehrlander, Mary. “Walter Harper, Alaska Native Son.” UAF Summer Sessions & Lifelong Learning. Via YouTube. 7/7/2018. https://www.youtube.com/watch?v=9-FrvS3gONg Farquhar, Francis P. “Henry P. Karstens—1878-1955.” The American Alpine Club. https://publications.americanalpineclub.org/articles/12195611200/Henry-P-Karstens-1878-1955 Hayes, Alan L. “One Congregation, Two Cultures: St. Mark’s Episcopal Church Nenana, Alaska.” Anglican and Episcopal History, vol. 68, no. 1, 1999, pp. 141–46. JSTOR, http://www.jstor.org/stable/42612013. Accessed 24 Nov. 2025. James, David A. “In story of the legendary ‘Walter Harper: Alaska Native Son,’ Denali is just the beginning.” Alaska Daily News. 12/16/2017. https://www.adn.com/arts/books/2017/12/16/in-story-of-the-legendary-walter-harper-alaska-native-son-denali-is-just-the-beginning/ James, David. “The Brief, But Bright Story of Walter Harper.” Alaska. 5/21/2022. https://alaskamagazine.com/authentic-alaska/the-brief-but-bright-story-of-walter-harper/ John, Peter. “The Gospel According to Peter John.” Krupa, David J., editor. Alaska Native Knowledge Network. 1996. https://ankn.uaf.edu/publications/Books/Peter_John.pdf Johnson, Erik. “Honoring the Unsung Heroes of the 1913 Summit Expedition: Esaias George and John Fredson.” National Park Service. https://www.nps.gov/articles/000/dena-history-unsung-heroes.htm Johnson, Erik. “The Ultimate Triumph and Tragedy: Remembering Walter Harper 100 Years Later.” National Park Service. Denali National Park. https://www.nps.gov/articles/dena-history-harper.htm Manville, Julie and Ross Maller. “The Influence of Christian Missionaries on Alaskan Indigenous Peoples.” Interdisciplinary Journal of Research on Religion. Vol. 5, Article 8. 2009. Miller, Matt. “‘May Light Perpetual Shine Upon Them.’” KTOO. https://www.ktoo.org/2013/10/26/may-light-perpetual-shine-upon-them/ New York Times. “Yukon Indian Opens Coney Island Eyes.” 6/1/1914. Stuck, Hudson. “A winter circuit of our Arctic coast; a narrative of a journey with dog-sleds around the entire Arctic coast of Alaska.” New York. C. Scribner’s Sons. 1920. https://archive.org/details/wintercircuito00stuc/ Stuck, Hudson. “Ten Thousand Miles With A Dog Sled a Narrative of winter travel in Interior Alaska.” 1917. https://archive.org/details/tenthousandmiles0000huds/ Stuck, Hudson. “The ascent of Denali (Mount McKinley) a narrative of the first complete ascent of the highest peak in North America.” New York, C. Scribner's Sons. 1914. https://archive.org/details/ascentofdenalimo01stuc/ Stuck, Hudson. “Voyages on the Yukon and its tributaries: a narrative of summer travel in the interior of Alaska.” New York : Charles Scribner's Sons. 1917. https://archive.org/details/cihm_76545/ Walker, Tom. “A Brief Account of the 1913 Climb of Mount McKinley.” Denali National Park and Preserve. https://www.nps.gov/dena/learn/historyculture/1913ex.htm Woodside, Christine. “Who Led the First Ascent of Denali? Hudson Stuck, Archdeacon of the Yukon.” Vol. 63, No., 2 Summer/Fall 2012. See omnystudio.com/listener for privacy information.

Join Mark, Eva and Fome as we discuss anything and everything Grand Archive TCG. We chat gameplay, finance, lore and much more. On this extended episode, we weeb out about our adventures from Ascent Akihabara before giving our "Trash or Gas" verdicts on some very intriguing Phantom Monarch cards!LINKSFractal of Insight by mDuo13https://fractalofin.siteGot a Question for TalkGA? Youtube: Comment on this Video, include #TalkGAEmail: talkgapodcast@gmail.com with subject #TalkGATweet at us: https://twitter.com/TalkGA_PodcastMeet Our Co-Hosts:Eva (Twitter): https://www.twitter.com/waterpixievaEva (Youtube): https://www.youtube.com/@waterpixievaFome (Twitter): https://www.twitter.com/at_fomeFome (Youtube): https://www.youtube.com/@FomeMark (YouTube): https://www.youtube.com/@SolarGamesllcMark (Twitter): https://twitter.com/solargamesEva - Video EditingFome - Recording, Audio Edit, ThumbnailMark - Distribution===MUSIC===Background Music: Lofi GeekCheckout Lofi Geek's Channel:https://www.youtube.com/channel/UCyD59CI7beJDU493glZpxgA#grandarchivetcg #grandarchive #gatcg Hosted on Acast. See acast.com/privacy for more information.

What if your biggest setback is actually setting you up for your greatest comeback? Josephs story reveals how God takes us low to bring us high, using our trials to prepare us for our calling. Even betrayal and failure cant stop Gods redemptive plan. The post Descent Before Ascent appeared first on Emmaus Road Fellowship.

I, sir, I honor you my proxy And what will with what you make take of that, my beast and brawn affronted; That to no matter to which I may stand as though offered to the Gods, I am at bare my force and wary feast upon thy eyes as swarms, And then to no may have you since! I am at all, my eye, your arm, And hallowed crucifix! CHAOS shatters into a FIRE of FEATHERED fury and precedent mercury of volcanic embering magma and sparse clouds of silver and gold, while though first bleeding from the mouth he is engulfed in flame at once, becoming not unlike the Phoenix, a galaxy into his own forever escaping and never ending realms. Ahhh, you're right. YO WHAT THE FUCK DID I JUST SEE? That's ludicrous! ah huh, I know, right. You took all that? Yep. {Enter The Multiverse} Sire, Your honor. I am bound. I have been forged. The crown. Certainly. Your high marks! Aye… You've been betrayed. …To no doubt. I am obliged to confront, your majesty, at all hours and in this your fortress— —your honor— And Chaos, that this, though there be your throne, Cannot bear weight of rock and stone to rebel archer, That which I am tied to seek, dear honor, Your vary mercy that there I, Here too, am slain! Damn. Creep shit, huh. Yeah. Why does Colbert get all the best parts?! Because he's capable of reading these types of monologues from cue cards! That circuit. He has a bigger cause than you know. [Redacted] It wasn't that I thought I was actively being watched, but more along the lines of knowing for a Friday, my mind wouldn't drift elsewhere and upward beyond, to the sixth, seventh, 8th or 15th floors— or whatever other crazy shit was apparently above them. Secret places I knew of and often thought about, but not too hard. It boggled my mind what was beyond and out of focus from the lower realms of New York, where it was dark and often dirty and hurtful to even wander. My breaths became deep and hollow; They won't turn your face to you, But they will burn through your whole world, wanting you undone Following sealing knives, half have no concious And tethered tongues— This is Levels, Watch us This is Levels, On your mark, This is levels, Christ conscious, This is Levels, Boats on the dock, Storm water, Pure thoughts of harm, But also luck, Drifting in that same water, Ducks, Not known in here our land, or others. You are no longer closer nor called for what you want It doesn't get that much more simple, nor more complex It doesn't get less disheveled than ‘anyway.' I suffer surface just to suffice this sauna trap It doesn't get any less leveled that two tall towers, September 11th. It doesn't get differentiated or dismissed, either, Without press involvement You got to love an easy bake oven and a handful of drama; You've got to love the plausible options for objections and motions to show cause You have got to love old folks and hard laughs, got to! You've got to love the cosmos for at least trying to show us God back, Though god turned back on us a month ago, Or so it was written More hard times And more cold half's And limbs lost, and marks and mauve and cranberry fortunes. More dusks and more dawns and more mortals but no heart left; No call to arms if you were worn backwards for your half. Now time for the calm but the ball bearings not lose but close hard down when you tip the nose up not to dive but force up the wheels as lifting planes does but you are donuts and dusk and dawn, and you are clutching stones in pockets, Four for corners of those the rock has, And that, North south, East west, And these days give gratitude, For wire stakes and high makes this time for more time deaf authors, Still no mortal walk has I, And still indifference to her call, my fortune is in death which may be cause to no one to suffer, As I have not love, And I have not friends, And I have not bonded and therefore this betrayal from where there speaks my meadow and assault have again lied, as devil does against all time. And so I smile, there, and welcome death, form withered birds did wander and then, before my eyes evolved to dust which then did sparkle, And there setting into scattered grains of sand. For which her shores were thought of, not as birds, but sure enough as rocks to till and thunder; And magnanimous waves you did there found I, Making graves and also these as caves, and banks, and ways to think her mazes as a construct. So now there, you are conformed, And all but may you came to offer. So there then shall tipping this and waves had planted oceans from my martyrs, And so again I called to brothers and also the fathers formed, as I had thought to know, these times and others as a motion [to show cause] So shattered banks and blanks my checkbook, scattered eyes though blue have yet been battered black and darkened; And also that became of which her office was unboxed, there was no work there, For her thoughts had caused the forests and winds to suffer from her art, therefore. There is no homeland, now or here or either, Shall I wonder? And then frayed her mark and also frayed this flag did fly for shame and horror. So there, did also Chaos sit and lack and gripping rope upon there crosses, also did my eye to mind, Him to a rope, but had departed. So I watched him hang from the noose, Though loosened grasp from known the ballet dancer, also then became the rabbit This of past and present. Ah, Fuck with me. I want you to. Aye aye. What is his power? Just wait for it… I don't think this is what you want it to— Just wait. Just listen? Listen to what? The man is just— blabbering. The cadence in his voice though; it's a rhythm. What, The cadence! In his voice— Mm. McDonald's. Okay?! But why are you saying—? Wait a minute. Wait what?! Play the tape back, and boost the audio. What for. Just do it, Mark. This costs a fortune and he's taking up all of our— THE MAN IN THE BOX has exploded. — time. What just happened. I told you he would do it. And we missed it. I don't get it. Where is he? There's no way of knowing yet. Check the grid. It's not… that simple…. Well then! Check the cadence. Or something ! Whatever you said. Jesus, I hate these alien motherfuckers! He's not an “alie What—? He's just— I mean— I do not understand. —he's human he's just— these ancients are gifted with— [sort of] Gifted?! You call that gifted?! He exploded into a fireball of feathers and— whatever this is— what is it?! It appears to be volcanic ash, sir. WHAT?! I'm moving backwards, forwards, backwards— forward time and time is dust from now on, I am in the end of my shattered and half lived life, Though bonded body to not my soul, which seeks not love and light, the morsels of the marker of my kind, And this to fill my aching desire to—- — now you've gotta run. From what? THE— AAAAhahsHAHSHjhabdbsnNadbdbamamBSBDNAGAGHAHghahsbabahaa!! WHAT WAS THAT. I DONT KNOW. I JUST HAD SIX ORGASMS. [BLACKOUT.] {Enter The Multiverse} DANE COOK wakes up from a VERY HARD NAP. …what just happened? This is your fault. You caused that. Okay. Gun in my face. I've had things, but not that. Get up. Jesus Christ. Just calm down. This is my calm. [The Festival Project ™] Do not panic. What the fuck are you telling me. Just stay calm. Do not panic. Don't panic what! That. Oh. You showed us what you are. No I did not. You want that? Uh… CC Just when you think you have me all figured out, I promise, it's not that. He has a gun! Fall back! Oh shitsauce, what in the fuck is going on! I may have had to stop and think for a moment ‘Where the fuck was I going?” The problem was I knew I already had the answer, and it was “Nowhere, fast.” Maybe even faster than ever. That hollow pit inside my stomach was calm now because most of all, I wasn't on the subway, I was on autopilot somewhere way far off from my body. Train me not, For this I die as one and always Sure to come for what is known and also for my martyr. Soon to fall I, bitter from the rock And drifting intermittent conscious, The constant not to known, But just a trough to all our horses. So this shame and guilt and rit and raft which I whitewater, so then to shall be betrayed as so they say I am, for now and onward. So her force is death and her tip have sung and those caves we made were of not fortune, but gloom and pity, merriment and pepper peer to socket and For now, my broken. Withered here and there And for to curse, But not to save my cycle, Dim this light for this I offer sacrament, Married waves and crevices of canyons I had watered, and then to twist of pine and though my time was won as always, want. The tip and twist of time would trim her down of those as slaughtered. Giving time and giving hate, and giving twins, And giving tin and giving golden graves, for maids And golden trophies. Giving taste and giving waste and giving ghosts wool coats for courthouses, Giving dim and dinner to these flames for which were ordered, have I. Giving those is taste and giving those is feasts, and giving those is masonry, created in her honor; Giving those is peace and wars, And to left ties, a peril force And giving these is tales and miners Trapped in these there caves as though you drift in barren lands. Well! Well. If I don't know who it is And I don't know what it is What I can't catch Man, Just leave the the fuck alone already, Would you? I have to wonder why I even come here, Full frozen How I'm running on low fuel, But just a sure to fact— (((Huh.))) Yeah, I recognize that dudes voice at this point Alright, maybe I am being followed. Yeah, that can't be a coincidence. It could. It is the rock. No it couldn't, Cause it's the rock. INT. ROCKEFELLER PLAZA. SUNRISE Okay, it's pretty from every angle! My fingers are frozen. Can I go inside now?! Yes. Here is the entrance. Jesus Christ! {Enter The Multiverse} Jesus All Day Christ. What are you looking at? I don't know yet. L E G E N D S It's pizza time. It's Kimmel time. [redacted] These are dangerous thoughts. Oh no, I turned my mind off. I love Kimmel, but I lost focus. Maybe this was the hour I needed without timing my life out. Then again, I did just recently watch him burst into flames in my living room. I have to wonder what that's about. Socumopolus Open On The Operating Table. Symposium, 2025/2026 TBA -Ū. Prod. By Blū Tha Gürū Symposium is a concept album that reinterprets the ancient Greek tradition of philosophical dialogue for the modern age. Taking its name from Plato's seminal text, which structured profound conversations about Love (Eros) as a series of distinct speeches, this album presents a series of intense, mythic narratives—the tracks—that each serve as a unique speech on the nature of consciousness, suffering, and transcendence. The album's unconventional structure, with initial tracks sporting double titles (e.g., forgetmenots.//follow through.), reflects the complex philosophical dualism explored throughout the work—the conflict between the body and the mind, the real and the dream, the past and the imperative to move forward. Each long-form track is a deep dive into an extreme mental state, an attempt to define the core truth of existence through an absurd or heightened reality. [Socumopolus Open On the Operating Table] This track is a visceral representation of the album's Platonic core. It is a grueling philosophical thought experiment set to music made to be experienced as though sifting through a gallery; as interpretive art rather than festival minded electronic dance music. ‘Socumolopus' opens in the uncomfortable and disjointed stairway of becoming undone at the midst of a medical mercy— unable to move or act with the understanding and awareness of a total loss of autonomy and control. A complete paralysis, but not of thought. Socumopolus Open On the Operating Table tells the story of a man undergoing high-risk, life-saving surgery. Due to a failure in anesthesia, he is trapped in a state of conscious paralysis—unable to alert the surgeons, yet fully aware as the operation unfolds. Indeed he reaches a certain purgatory of sorts and a certain death, as he becomes outward of himself enough to realize he knows nothing of this self, even his own name which he is called. He is now only Socumopolus. He is forced to watch his own body being opened, simultaneously experiencing the surgery from the table and from an out-of-body perspective above., however, once the initial shock of the blood and gore of his organs unraveling on the table before him, he drifts between lucid galaxies and worlds, traveling beyond all known time. His consciousness drifts in a purgatory spanning what is hours, but is rather eons in his own unaligned infinite outer consciousness, mingling the visceral reality of the operating room with non-sequitur dreams and the background noise of the hospital's televisions, and in and out of worlds alike; but also unknown. Symposium: A Concept Theory The track is a direct musical translation of Plato's Dualism—the belief that the mind/soul is separate from the physical body. [The Body] The character's physical being is the object of suffering (the operating table), imperfect and subject to the knife. [The Soul] His consciousness detaches, viewing the scene from above—this is the transcendent perspective, attempting to find "The Form of Truth" outside the confines of the suffering body. The character's hours-long, suspended state—neither fully alive nor dead, neither fully conscious nor dreaming—is the album's metaphor for the Ladder of Ascent in the Symposium. He is stuck in the intermediate steps, struggling between the earthly, mortal reality and the potential for a higher, purer vision, while the surrounding hospital noise and fragmented dreams represent the strange, sometimes absurd "speeches" (like Aristophanes' myth) that interrupt the pursuit of ultimate truth. In Socumopolus Open On the Operating Table, the operating room becomes the stage for a private, intense symposium on what it means to be aware when the self is literally dismantled. The surreality is not in the musicality, but the concept of the artwork itself, which reads most like an awkward statue or sculpture stationed distinctly in the way of a place you least expected, or perhaps even dead-center your normal course. It blocks the path with the cause to force you to think of creating an alternate route, or to travel or explore beyond what is familiar or known— or perhaps— just to force you to think at all when you may suppose the rest can just be turned off, as you cross out or autopilot and into a newfound structure for your own immortal cause. Thank You for Listening. Chroma 111. The Shoestring Theory. Copyright © The Complex Collective 2025 The Festival Project, Inc. ™ All rights reserved. Chroma111. Copyright © The Complex Collective 2025. [The Festival Project, Inc. ™] All rights reserved. UNAUTHORIZED REPRODUCTION OR DISTRIBUTION IS STRICTLY PROHIBITED BY LAW. INFRIGMENT IS PUNSHABLE BY FEDERAL LAW

Welcome to Day 2751 of Wisdom-Trek, and thank you for joining me. This is Guthrie Chamberlain, Your Guide to Wisdom – Theology Thursday – From Eden to New Jerusalem: The Pattern of Ascent, Fall, and Redemption Wisdom-Trek Podcast Script - Day 2751 Welcome to Wisdom-Trek with Gramps!   I am Guthrie Chamberlain, and we are on Day 2751 of our Trek.   The Purpose of Wisdom-Trek is to create a legacy of wisdom, to seek out discernment and insights, and to boldly grow where few have chosen to grow before. Our current series of Theology Thursday lessons is written by theologian and teacher John Daniels. I have found that his lessons are short, easy to understand, doctrinally sound, and applicable to all who desire to learn more of God's Word. John's lessons can be found on his website   theologyinfive.com.   Today's lesson is titled From Eden to New Jerusalem: The Pattern of Ascent, Fall, and Redemption. Throughout Scripture, a pattern emerges—one that contrasts the fall of those who grasp at divinity with the exaltation of those who receive it by grace through believing loyalty. From Eden to Hermon, Babel, and ultimately to the New Jerusalem, the Bible traces the path of human ambition, divine descent, and final restoration. The first segment is: Eden: Seizing Divinity, Ending in Death In the beginning, Adam and Eve were created in the image of God, placed in sacred space, and destined to reign with Him. Yet they were not content to reflect His glory. Tempted by the serpent, they reached for equality with God on their own terms: “For God knows that when you eat of it your eyes will be opened, and you will be like God, knowing good and evil.” Genesis three verse 5 By attempting to grasp what had not been offered, they fell. Cast out of the garden, barred from the Tree of Life, and sentenced to die, their descent began not just physically but spiritually. They traded divine fellowship for exile and mortality. The second segment is: Hermon: Divine Rebellion and the Corruption of Mankind The next great rebellion came not from humans alone, but from the spiritual realm. According to 1 Enoch 6, the sons of God descended upon Mount Hermon and made a pact to defy God by taking human wives and producing the Nephilim. Their actions unleashed chaos and violence across the earth. This attempt to force a merger of heaven and earth on their own terms brought catastrophic consequences. God judged the Watchers, bound them in the Abyss, and destroyed their offspring in the Flood. Yet their spirits—demons—remained to corrupt mankind. The descent from Hermon marked not exaltation but divine exile, and it echoes the same pattern: those who attempt to seize divine authority fall into judgment. The third segment is: Babel: Ascending in Pride, Scattered in Judgment The next great act of rebellion came at Babel. Humanity, unified in language and purpose, sought to reach the heavens: “Come, let us build ourselves a city and a tower with its top in the heavens, and let us make a name for ourselves…” Genesis Eleven verse 4 Though the text says they were “one people,” this unity was likely driven by demonic influence—a renewed attempt to reopen the spiritual gateway severed at the Flood. Some modern theological reconstructions suggest the builders, influenced by demonic forces, may have sought to create a gateway that would allow the imprisoned Watchers to rise again and make war on Heaven itself. But the plan was doomed. God had already sentenced the Watchers to the Abyss, and no human or spiritual force could overturn that...

Dr. Drago and Dr. Traina continue their discussion of breakthrough developments in triple-negative breast cancer treatment, sharing highlights from the promising ASCENT-04 trial results with sacituzumab govitecan plus pembrolizumab in first-line treatment. They also address key clinical challenges around sequencing antibody-drug conjugates and managing interstitial lung disease toxicity.

Most people talk about space power like it's a solved problem. Big arrays, rigid panels, high-efficiency silicon; the same architecture we've been flying for decades.  But the more you look at where national security and commercial space are headed, the clearer it becomes: our power systems weren't designed for the missions we're trying to execute today. Space is no longer a passive environment. It's dynamic, congested, competitive, and increasingly contested. If you're operating a satellite that needs to reposition, evade, maneuver, or maintain persistent awareness over the oceans, every kilogram of mass and every square inch of surface area starts to matter. Traditional solar arrays generate plenty of power, but they come with a hidden cost: fragility, deployment complexity, and a form factor that locks spacecraft into decisions they can't easily undo. Thin-film solar panels change that. When you can generate meaningful power without rigid wings. When your power source can be wrapped around a body, integrated into a surface, or rolled out without fear of shattering, Maneuverability becomes an asset instead of a liability.  High-radiation orbits are more viable, high-voltage architectures make sense, and persistent maritime sensing becomes more realistic. And the same characteristics that matter in orbit start unlocking terrestrial defense applications as well. What are some of the new opportunities arising for thin-film solar? How are they able to ability to fulfill smaller, specialized, high-value orders quickly? In this episode, I sit down with the CEO of Ascent Solar, Paul Warley. We talk about how thin-film is reshaping what's possible in orbit, why defense customers are paying attention, and how a microcap manufacturer found itself aligned with some of the biggest trends in national security and space power.   You'll also learn; Why maneuverability is becoming the real strategic advantage in orbit How thin-film's flexibility and high-voltage capability unlock new spacecraft architectures Why reaching 12–13% efficiency is a tipping point that suddenly makes thin-film viable for LEO, MEO, and even high-radiation GEO missions. How defense customers are rethinking power as mission profiles shift Why thin-film's resilience in high-radiation and atomic oxygen environments gives it advantages that silicon can't match. What the increasing launch cadence means for power requirements, mass budgets, and the economics of spacecraft design. How decades of sunk R&D and process knowledge create a moat that would be difficult and expensive for new entrants to replicate. Where Paul sees thin-film fitting into the future of both defense and space operations, from niche platforms to major programs. About the Guest Paul Warley is the President and CEO of Ascent Solar, a small microcap company in Colorado. Ascent's thin-film is the solar power solution for scenarios where traditional rigid panels won't work. Ascent brings together 20+ years of R&D, 17 years of manufacturing experience, numerous awards, and a comprehensive IP and patent portfolio to cement its leadership in the photovoltaics market. To learn more, visit https://ascentsolar.com/.  About Your Host Craig Picken is an Executive Recruiter, writer, speaker, and ICF Trained Executive Coach. He is focused on recruiting senior-level leadership, sales, and operations executives in the aviation and aerospace industry. His clients include premier OEMs, aircraft operators, leasing/financial organizations, and Maintenance/Repair/Overhaul (MRO) providers, and since 2008, he has personally concluded more than 400 executive-level searches in a variety of disciplines. Craig is the ONLY industry executive recruiter who has professionally flown airplanes, sold airplanes, and successfully run a P&L in the aviation industry. His professional career started with a passion for airplanes. After eight years' experience as a decorated Naval Flight Officer – with more than 100 combat missions, 2,000 hours of flight time, and 325 aircraft carrier landings – Craig sought challenges in business aviation, where he spent more than 7 years in sales with both Gulfstream Aircraft and Bombardier Business Aircraft. Craig is also a sought-after industry speaker who has presented at Corporate Jet Investor, International Aviation Women's Association, and SOCAL Aviation Association.  Subscribe, Rate & Review Check out this episode on our website, Apple Podcasts, or Spotify, and don't forget to leave a review if you like what you heard. Your review feeds the algorithm, so our show reaches more people. Thank you!   

Dec 9, 2025 – Rising geopolitical tensions are pushing global capital and institutions to seek out safe havens. Enter Singapore—a strategically neutral powerhouse—and gold, the world's ultimate safe-haven asset. The intersection of these two forces...

In this episode of the Conscious Fertility Podcast, Dr. Amit Goswami—quantum physicist, author, and pioneer in bridging science and spirituality—returns to discuss his latest book, The Ascent of Humanity: Quantum Biology and Our Future. Dr. Goswami reveals why life cannot be explained by molecular biology alone and how consciousness is the true foundation of existence. He explains how aligning our intentions with the movement of universal consciousness can transform not only our individual lives but also the evolutionary trajectory of humanity.This conversation blends science, philosophy, and practical insight to inspire listeners to join the movement of consciousness shaping our shared future.Key takeaways:Biology needs consciousness — Life is more than molecular chemistry; consciousness is the driving force of evolution.Manifestation isn't ego-driven — True creation happens when our intentions align with the purpose of universal consciousness.Software over hardware — Changing our beliefs and emotional patterns (“software”) can transform our biology (“hardware”).The quantum gap fuels creativity — Insight and innovation emerge from openness, surrender, and connection to consciousness.Participation is essential — Transformation happens when we actively join the movement of consciousness, not wait passivelyDr. Amit Goswami's Bio: Dr. Amit Goswami is a theoretical quantum physicist and retired professor from the University of Oregon, where he taught for nearly 30 years. He is a pioneer in bridging science and spirituality, best known for his solution to the quantum measurement problem and his development of a science of consciousness. Dr. Goswami is the founder of the Quantum Activism movement and Quantum Activism Vishwalayam, an educational institution in India focused on transformative learning grounded in quantum science. He is the author of numerous influential books, including The Self-Aware Universe, The Quantum Doctor, Quantum Spirituality, and his latest, The Ascent of Humanity: Quantum Biology and Our Future, Where To Find Dr. Amit Goswami: Website: https://amitgoswami.org/Center for Quantum Activism : https://www.cqaedu.com/ Books:https://www.amazon.com/stores/Amit-Goswami/author/B0028OI2UQ?qid=1372141556&sr=8-2-ent&ref=ap_rdr&isDramIntegrated=true&shoppingPortalEnabled=true E-mail: info@amitgoswami.org Episode #62 of The Conscious Fertility PodcastQuantum Integrative Healing with Valentina Onisor & Amit Goswami

I am excited to share this conversation with my good friend and investor, Michael Novogratz, to discuss the state of the markets. We are experimenting with a new format, so please send us your feedback if you have any. This conversation cuts through the noise of crypto crashes, rate cuts, and AI hype with two veteran investors who've lived every boom, bust, and hallucination along the way. From macro politics to leverage-fueled panic and trillion-dollar tech bets, it's an unsentimental, sharp-edged tour of how money, power, and technology are colliding right now. Michael Novogratz is the Founder and CEO of Galaxy Digital. He was formerly a Partner and President of Fortress Investment Group LLC. Mr. Novogratz served on the New York Federal Reserve's Investment Advisory Committee on Financial Markets from 2012 to 2015. He serves as the Chairman of The Bail Project and has made criminal justice reform a focus of his family's foundation. Follow Anthony on X: https://x.com/Scaramucci Follow Novo on X: https://x.com/novogratz Anthony Scaramucci is the founder and managing partner of SkyBridge, a global alternative investment firm, and founder and chairman of SALT, a global thought leadership forum and venture studio. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Featuring an interview with Dr Priyanka Sharma, including the following topics: Endocrine therapy for hormone receptor-positive, HER2-negative high-risk localized breast cancer (0:00) Johnston SR et al. monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC). ESMO 2025;Abstract LBA13. Durvalumab in combination with neoadjuvant chemotherapy for localized triple-negative breast cancer (TNBC) (3:25) Loibl S et al. Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC) – Long-term analysis from the GeparNuevo trial. ESMO 2025;Abstract 292MO.  Efficacy and safety findings with TROP2-directed antibody-drug conjugates for metastatic TNBC (5:11) Cortés JC et al. Primary results from ASCENT-03: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i). ESMO 2025;Abstract LBA20.  de Azambuja E et al. Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in patients (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) in the phase III ASCENT-04/KEYNOTE-D19 study. ESMO 2025;Abstract LBA22.  Dent R et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial. ESMO 2025;Abstract LBA21.  CME information and select publications

Misinformation may often spread like wildfire on social platforms, but believe it or not, with the right tools, false stories and backlash can be contained just as quickly.In this episode of the DrMarketingTips Show, Jenn shares a special presentation on how healthcare practices can create a tactical social media game plan that protects the brand while still driving growth. This webinar was originally presented in collaboration with ASCENT, a community-driven educational organization for practice administrators in the ENT specialty.Tune in to Discover:How a false, racially charged TikTok post snowballed into global outrage, threats, and review bombingThe exact crisis playbook Jenn's team used: pausing content, issuing a CEO statement, and coordinating rapid responseWhich platforms to prioritize (and which to skip) for time-strapped practicesHow to use content pillars to avoid burnout and stay consistentPractical, HIPAA-safe ways to use AI for content and workflow without replacing human oversight

It's a battle in the corridors of the Zhuangzi as two factions within the Troubleshooters clash. ----more---- Bit of a boring lore dump in this one if you like that sort of thing :) Next week is the release of second part of The Law Of Salvage on YouTube and podcast, so stay tuned for that! The Patreon is usually ahead, check there first for early access episodes! ----more---- SOCIALS X: @nwtbugbear Facebook | YouTube | Instagram @NWTBPODCAST Patreon: https://www.patreon.com/NWTBPODCAST MUSIC Music by Karl Casey @ White Bat Audio https://karlcasey.bandcamp.com Music: Futuristic 3 and Novus Initium by Alexander Nakarada (creatorchords.com) Licensed under Creative Commons BY Attribution 4.0 License https://creativecommons.org/licenses/by/4.0/ All other sounds and effects are sourced from https://freesound.org using the Creative Commons 0 License.

As we head into the last days of 2025, it's time for our traditional look back at our favorite games and game-related events of the last 12 months. Discussions include: The best game shipping wrapper we've ever seen. A really impressive deck-builder that you can't get for love or money... ...or CAN you?  A game box even bigger than last month's! Blood on the Clocktower, but solitaire...and on a PC? Frank cheats and adds a computer game to his list, as usual...but so does Mike?!? What have we missed? What was your favorite board game of 2025? Come visit our Discord server to chat with us and other like-minded game nerds! As always, thank you for listening. Please consider writing us an iTunes review if you like what you hear! We'd also love to have you visit our website and let us know what kinds of games we should discuss next. You're also more than welcome to comment on the episode page, or our Discord, or our Facebook page, or tag @ascentofboardgames on Bluesky. Whatever way you prefer to share your opinions with us, we'd love to hear them.  As always, we appreciate your listening - stay safe out there, and happy gaming! Website: https://www.ascentofboardgames.com Email: ascentofboardgames@gmail.com Discord: https://discord.gg/tdH3QAn  Facebook: https://www.facebook.com/groups/ascentboardgames/ Bluesky: https://bsky.app/profile/ascentofboardgames.bsky.social Discord: http://discord.ascentofboardgames.com Instagram: https://www.instagram.com/ascentofboardgames/ And, very occasionally, Twitch: https://www.twitch.tv/ascentofboardgames Intro and outro music is "Evening Melodrama" by Kevin MacLeod (incompetech.com), licensed under a Creative Commons: By Attribution 3.0 License. The Ascent of Board Games is licensed under a Creative Commons Attribution 4.0 International License. Some rights reserved. Thank you for listening!

We all want to ascend to great heights. We all hope that we can accomplish our potential and unlock our opportunities. We all yearn for self-actualization and development. But it seems that the path of ascent is invariably bumpy. It seems that an ascent to great heights must entail numerous falls along the way. The […]

We all want to ascend to great heights. We all hope that we can accomplish our potential and unlock our opportunities. We all yearn for self-actualization and development. But it seems that the path of ascent is invariably bumpy. It seems that an ascent to great heights must entail numerous falls along the way. The righteous must fall seven times before ceasing to fall. Why must we fall in order to ascend? Why can't things be more straightforward? This question was posed on a rabbis panel that I participated in. In this podcast, I will share a powerful and provocative idea on the necessity of stumbles along a path of ascent. Plus, this podcast will also feature an interesting perspective on the delicate balancing act of social pressure and individuality.– – – – – – – – – – – – – – – – – – – – – –DONATE: Please consider supporting the podcasts by making a donation to help fund our Jewish outreach and educational efforts at https://www.torchweb.org/support.php. Thank you!– – – – – – – – – – – – – – – – – – – – – –Email me with questions, comments, and feedback: rabbiwolbe@gmail.com– – – – – – – – – – – – – – – – – – – – – –SUBSCRIBE to my Newsletterrabbiwolbe.com/newsletter– – – – – – – – – – – – – – – – – – – – – –SUBSCRIBE to Rabbi Yaakov Wolbe's PodcastsThe Parsha PodcastThe Jewish History PodcastThe Mitzvah Podcast This Jewish LifeThe Ethics PodcastTORAH 101 ★ Support this podcast ★

reference: Sri Aurobindo, Bases of Yoga, Chapter 3, In Difficulty, pp. 45-47This episode is also available as a blog post at https://sriaurobindostudies.wordpress.com/2025/11/25/ascent-and-integration-define-spiritual-progress-for-the-seeker/Video presentations, interviews and podcast episodes are allavailable on the YouTube Channel https://www.youtube.com/@santoshkrinsky871More information about Sri Aurobindo can be found at www.aurobindo.net  The US editions and links to e-book editions of SriAurobindo's writings can be found at Lotus Press www.lotuspress.com#Sri Aurobindo #yoga #integral yoga #spirituality

Cody and Felix analyze the Rams' "lie" defense and the Texans' physicality. Plus, previews for Ohio State vs. Michigan, Chiefs-Cowboys, and the full NFL Thanksgiving slate.—In this episode:- Texas & Oregon's Ascent: We discuss how Texas is peaking at the right time with Arch Manning and analyze Oregon's evolution into a “new blue blood” under Dan Lanning.- "The Game" Preview: We break down the Ohio State vs. Michigan matchup, highlighting the Buckeyes' dominance and Michigan's schematic regression under Wink Martindale.- Defensive Philosophies: We contrast the Houston Texans' physical, “punch you in the face” style with the Los Angeles Rams' deceptive, “everything is a lie” coverage disguises.- Rookie QB Realities: We examine the developmental paths of young quarterbacks, comparing Caleb Williams' need for structured creativity against JJ McCarthy's statistical struggles.- Thanksgiving Slate & Eagles Panic: We preview the holiday weekend games, predict a Chiefs win over Dallas, and discuss why the Philadelphia Eagles might be on the verge of a collapse.—Timestamps:00:00 Intro & Thanksgiving Break Chaos 01:10 Texas Dominance & Arch Manning's Ascent 04:38 Oklahoma's Defensive Identity vs. Mizzou 10:20 Can Lincoln Riley Fix USC? 12:26 Dan Lanning & Oregon as a “New Blue Blood” 17:00 The Game: Ohio State vs. Michigan Preview 19:33 The Wild ACC Playoff Picture 23:29 Texans Defense: “Punch You in the Face” Style 26:02 JJ McCarthy's Struggles & Vikings Issues 30:09 Jameis Winston & The Value of Backup QBs 35:32 Chiefs Find a Way (Again) & Latu's Interceptions 39:41 The Patriots' Historic Defensive Run 44:21 Is JSN the Best Receiver in the NFL? 45:16 Caleb Williams: Genius vs. Structure 51:26 Saints, Taysom Hill, & 13 Personnel Obsession 54:08 Don't Sleep on the Cardinals Defense 56:37 Rams vs. Bucs: “Everything is a Lie” Scheme 59:31 Ravens vs. Jets: A Win is a Win 1:01:44 Cowboys Stun the Eagles: Comeback Analysis 1:07:42 Thanksgiving Preview: Packers vs. Lions 1:08:52 Preview: Bengals vs. Ravens 1:10:09 Thanksgiving Preview: Chiefs vs. Cowboys—» Join Felix and Cody each Wednesday as we dive deep into the game we love!MatchQuarters is a reader-supported publication. So, make sure to subscribe.—© 2025 MatchQuarters | Cody Alexander | All rights reserved. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.matchquarters.com/subscribe

In the incredible final act of Plato's Gorgias (481–527), Dcn. Harrison Garlick and Dr. Greg McBrayer (Ashland University, New Thinkery podcast) tackle the longest and most brutal confrontation: Socrates versus Callicles, the most shameless, most ambitious, and—as Greg insists—nastiest character in all of Plato. Visit thegreatbookspodcast.com for our read schedule!Check out our COLLECTION OF GUIDES to the great books.Go to THE ASCENT to receive two spiritual lessons a week.Callicles storms in threatening to “whoop Socrates in the mouth” and delivers the most radical claim yet: conventional justice is a sham invented by the weak; by nature the superior should rule, take more, and live without restraint—coining the first recorded “law of nature” in Western literature to mean might makes right (482e–484c). Socrates flips the argument, forces Callicles to admit intelligence without self-control is mere cleverness, and reduces his unlimited-pleasure principle to absurdity with the leaky-jar and escalating vulgar examples (constant scratching, the catamite, 494–495), provoking Callicles' outraged “Aren't you ashamed?”—proof he still clings to the noble (kalon) despite his bravado.At 503a Socrates finally reveals the two kinds of rhetoric: the shameful, flattering kind that seeks only pleasure, and the true, noble rhetoric that “makes the souls of citizens as good as possible” and strives to say “what is best” whether pleasant or painful—the kind Socrates claims to be the only Athenian practicing (521d). When Callicles becomes completely recalcitrant, Socrates turns to the audience with the unforgettable myth of naked souls judged by dead judges (523a–527e): every injustice leaves visible scars no rhetoric or power can hide; the cosmos itself is ordered toward justice and will not allow injustice to triumph forever. Athens is about to execute its only true statesman, but the myth promises that in the final reckoning Socrates' just soul will shine while his accusers' scarred souls stand exposed. The dialogue ends not with Callicles' conversion but with Socrates' quiet vindication: living justly is ultimately worth it, even in a city that kills its best citizen. Next week: a short break from Plato for Flannery O'Connor's “The Lame Shall Enter First.”

Psalms of Ascent, Cadence. For more resources on reading through the Bible in a year, visit my church's website at this link or text us at 888-644-4034. God bless - Doyle See omnystudio.com/listener for privacy information.

In this teaching, Pastor Gary closes our journey through the Songs of Ascent by looking at the final two psalms the ancient pilgrims sang as they entered Jerusalem. Psalm 133 celebrates the beauty of unity—brothers and sisters walking the same path toward God. Unity isn't easy, but it grows when we see each other as God's anointed people, and when the Holy Spirit softens our hearts through pouring out new life. Where unity exists, God commands blessing.Psalm 134 is the pilgrims' final response: “Bless the Lord.” Having arrived at the temple, they lift their hands in worship. We do the same today—praising God for saving us, sustaining us, and leading us on. The Songs of Ascent begin with “Woe is me” and end with “Bless the Lord.” That is the path of every Christian pilgrim: from struggle to worship, from journey to joy!

Bring a Friend, Save $200 @ Michael's New Year's Meditation Retreat in Costa Rica:  https://events.agapelive.com/awaken-to-a-new-year-of-possibility/ Today, Michael welcomes Dr Espen Wold-Jensen. Dr Espen is a researcher in Neuroscience and Quantum Physics, a Conscious Business Mentor, and a Multi 7-Figure 'SoulPreneur' who teaches his clients how to use the power of their own consciousness to turn obstacles into opportunities. Dr Espen went from having two broken legs and nearly succumbing to a hospital infection to healing himself from the inside out. His signature event, the Quantum Experience, delivers the same art, science, and application of consciousness that has transformed the lives of clients in over 12 countries. Conversation highlights: -The Accident That Changed Everything: The emotional suppression that led to a 2006 motorcycle crash, broken femurs, spine/pelvis fractures, and a long recovery -"Go Home and Breathe:" A moment of grace: receiving an inner directive to leave the hospital and start a specific breath practice, leading to the beginning Quantum Breathwork -You Are the Healer: How innate intelligence heals; while medicine supports, inner sovereignty and practice restore wholeness -Turning Pain Into Power: Reframing past hurts with purpose and gratitude; change the meaning, change your life -Quantum Explained Simply: We are 99.999…% "empty space"; our attention collapses possibility into form—when we raise our frequency, we change our outcomes -The Alchemy of Emotion: Transmuting fear?love, guilt?gratitude, shame?self-worth, grief?grace to heal relationships and reality -Emotional Healing Protocols: "Issues in the tissues"—clear lower-frequency emotions to shift habits and health -Out of Survival, Into Sovereignty: Media conditioning and fear states, and reclaiming executive function and heart coherence -Childhood Imprints & Programs:  The first 7 years wire beliefs about money, love, safety; you don't have "problems," you have programs -Inside the 3-Day Curriculum: Descent (past), Presence (truth), Ascent (future design) across eight centers; and more! Finally, Michael leads a guided meditation on focusing our intention + attention.

From College Engagement to Radio Stardom: Ronald Reagan's Ascent to the Hollywood B-List. Max Boot discusses how Ronald Reagan's father, Jack, secured a job as an administrator of welfare for the New Deal in late 1933. Meanwhile, Ronald developed into a successful young football star at Eureka College, where his steady girlfriend was Margaret Cleaver, known as Mugs. They were deeply in love and engaged to be married, but after graduation they separated, and Margaret, following a trip to Europe, fell in love with an American diplomat and returned the engagement ring to a crushed Reagan. Margaret's father, the Reverend Cleaver, was highly influential, acting almost as a surrogate father to Dutch Reagan. Dutch Reagan possessed a magnificent, compelling voice for storytelling and, graduating from college in 1932, recognized that while movie studios were absent from the Midwest, radio stations were plentiful. He landed his first radio job in Davenport, Iowa, and quickly succeeded, transferring to a larger station in Des Moines, where he became a very successful sportscaster known throughout the Midwest as Dutch Reagan, the voice of the Chicago Cubs and the White Sox. In Hollywood, Reagan was recognized as a heroic figure with a consistently sunny disposition and initially started in B-pictures at Warner Brothers. Reagan's movie career generated good income, and he demonstrated responsibility by moving his parents out to Hollywood. He met actress Jane Wyman at the Warner Brothers commissary, and they were married in January 1940.